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creased release of high molecular weight HA in the synovial fluid
and enhanced aggregating potential for cartilage proteoglycans.
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Purpose: To determine whether Tai Chi or hydrotherapy classes
for people with chronic symptomatic hip or knee osteoarthritis
(OA) can result in measurable clinical benefits.
Methods: A randomised controlled trial was conducted among
152 people, aged 59 years and over, with chronic symptomatic
hip or knee OA. Participants were randomly allocated for 12
weeks to hydrotherapy classes (n=55), Tai Chi classes (n=56) or
waiting list control (n=41). Outcomes were assessed at 12 weeks
(post treatment) and 24 weeks (sustainability) after randomisa-
tion and included pain and physical function (WOMAC), general
health status (SF-12v2), psychological well being and physical
performance (‘up and go’, 50 ft walk time, timed stair climb).
Results: At the 12 week post treatment assessment, 49%
(n=27), 34% (n=19) and 15% (n=6) of participants allocated
to hydrotherapy, Tai Chi and control group, respectively, were
treatment responders according to OMERACT-OARSI responder
criteria D. The difference in treatment responder rate between
the three allocation groups was significant (chi-squared=12.4, df
= 2, p=0.002). Compared with control, participants allocated to
hydrotherapy classes demonstrated mean improvements (95%
confidence interval) of 6.5 (0.4 to 12.7) and 10.5 (3.6 to 14.5)
for pain and physical function scores (range 0-100), respectively,
while participants allocated to Tai Chi classes demonstrated im-
provements of 5.2 (-0.8 to 11.1) and 9.7 (2.8 to 16.7). The 95%
CI for treatment effect sizes for physical function for hydrotherapy
or Tai Chi classes ranged from moderate to large (.50 to .76).
Both class allocations achieved significant improvements in the
SF-12 physical component summary score, but only allocation to
hydrotherapy classes achieved significant improvements in the
measures of physical performance. All significant improvements
were sustained at 24 weeks after randomisation. In this almost
exclusively Caucasian sample, class attendance was higher for
hydrotherapy with 81% attending at least half of the available 24
classes, compared with 61% for Tai Chi.
Conclusions: Access to either hydrotherapy or Tai Chi classes
can provide sustained improvements in pain and physical func-
tion for many older, sedentary people with chronic symptomatic
hip or knee OA. The improvements achieved in physical function
were greater than those demonstrated for traditional land-based
exercise programs.
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Purpose: To compare the clinical effectiveness, functional out-
come and patient satisfaction following intra articular injection
with Synvisc® and Hyalgan® in patients with osteoarthritis (OA)
of the knee
Methods: 356 consecutive patients with OA of the knee were
randomized into two groups to receive Hylan G-F-20 -Synvisc
(n=184) or Sodium Hyaluronate -Hyalgan (n=172). Weight bear-
ing radiographs were reviewed at baseline to grade the degree
of OA using the Kellgren-Lawrence system. All patients were
prospectively reviewed by blinded independent assessors at pre
injection, 6 weeks, 3, 6, 12 months. Knee pain and patient sat-
isfaction was measured on a VAS (0-10, 10 as worst pain).
Functional outcome was assessed using WOMAC, UCLA, Teg-
ner, Oxford knee score and EuroQol- 5D scores. Mean follow up
was 12 months
Results: The mean age of the randomised patients was 66.7 yrs.
Patients in both groups predominantly had grade III OA (Synvisc-
61% and Hyalgan-59%). There were no significant differences in
the age, sex and degree of OA between the two groups. Knee
pain on VAS improved from 6.7 to 3.2 by 6 weeks (p=0.02) and
was sustained until 12 months (3.7, p=0.04) with Synvisc. In
the Hyalgan group, pain improved from 6.6 to 5.7 at 6 weeks
(p>0.05) and to 4.1 at 3 months (p=0.04) but was sustained only
until 6 months (5.9, p>0.05). Improvements in the WOMAC pain
and physical activity subscales were significantly superior in the
Synvisc group at 3 months (p=0.02), 6 months (p=0.01) and 12
months (p=0.02). Similarly, the Tegner, UCLA and Oxford knee
scores were significantly better in the Synvisc group at 6 weeks
(p=0.02) and 6 months (p=0.03) and 12 months (p=0.04) post
injection whilst there was no difference between the groups at 3
months. There was no significant difference in the EQ-5D scores
at 6 weeks, and 3 months between the two groups. The EQ-5D
description scores were higher in the Synvisc group at 6 months
(p=0.03) and 1 year (p=0.04). General patient satisfaction was
better in the Synvisc group at all times although statistically
significant at 3 months (p=0.01) and 6 months (p=0.02). There
was local increase in knee pain in one patient who received
Synvisc, which settled by 4 weeks. Patient compliance was
99.2% in the Synvisc group as compared to 92.2% in the Hyalgan
group due to the number of recommended injections. There was
no difference in the cost of the drugs, but the total treatment cost
was 23% more in the Hyalgan group due to the two additional
visits to complete the course of treatment
Conclusions: Although both treatments offered significant pain
reduction, it was achieved earlier and sustained for a longer pe-
riod in patients with Synvisc. Patients treated with Synvisc have
demonstrated an early increase in activity levels as evidenced
by the WOMAC, UCLA and Tegner scores. Both treatments were
well tolerated, however, a local reaction of pseudo sepsis was ob-
served with Synvisc in one patient. The total treatment cost, both
for the patient and the hospital are higher with Hyalgan. From
this study, it appears that the clinical effectiveness and general
patient satisfaction are better amongst patients who received
Synvisc
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Purpose: Recently, attention has been attracted that oxidative
stress and its related chondrocyte aging have an important role
